BR0212915A - Uso de uma dose especìfica de sódio de fondaparinux para o tratamento de acs - Google Patents

Uso de uma dose especìfica de sódio de fondaparinux para o tratamento de acs

Info

Publication number
BR0212915A
BR0212915A BR0212915-9A BR0212915A BR0212915A BR 0212915 A BR0212915 A BR 0212915A BR 0212915 A BR0212915 A BR 0212915A BR 0212915 A BR0212915 A BR 0212915A
Authority
BR
Brazil
Prior art keywords
acs
treatment
sym
sulfo
specific dose
Prior art date
Application number
BR0212915-9A
Other languages
English (en)
Inventor
Anthonie Wilhelmus Arn Lensing
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0212915(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of BR0212915A publication Critical patent/BR0212915A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

"USO DE UMA DOSE ESPECìFICA DE SóDIO DE FONDAPARINUX PARA O TRATAMENTO DE ACS". A invenção refere-se ao uso de uma dose de 2,5 mg do pentassacarídeo metil O-(2-deóxi-2-sulfoamino-6-0-sulfo-<244>-D-glucopiranosil)(1<sym>4 4)-O-(ácido <225>-D-glucopiranosil urónico)-(I<sym>4)-O-(2-deóxi-2-sulfoamino3,6-dl-O-sulfo-<244>-D-gl ucopiranosil)-(1<sym>44)-O-(ácido 2-O-sulfo-<244>-L-idopiranosil urónico)-(1<sym>4)-2-deóxi-2-sulfoamino-6-O-sulfo-<244>-D-glucopir anosídeo ou um sal farmaceuticamente aceitável do mesmo para o preparo de um medicamento para o tratamento de Síndromes Coronarianas Agudas (ACS).
BR0212915-9A 2001-11-13 2002-11-07 Uso de uma dose especìfica de sódio de fondaparinux para o tratamento de acs BR0212915A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13
PCT/EP2002/012482 WO2003041722A1 (en) 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of acs

Publications (1)

Publication Number Publication Date
BR0212915A true BR0212915A (pt) 2004-10-13

Family

ID=8181220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212915-9A BR0212915A (pt) 2001-11-13 2002-11-07 Uso de uma dose especìfica de sódio de fondaparinux para o tratamento de acs

Country Status (37)

Country Link
US (1) US20040248848A1 (pt)
EP (1) EP1446131B1 (pt)
JP (1) JP4523276B2 (pt)
KR (1) KR20050044318A (pt)
CN (1) CN1602197A (pt)
AP (1) AP1820A (pt)
AR (1) AR037291A1 (pt)
AT (1) ATE361753T1 (pt)
AU (1) AU2002351915B2 (pt)
BR (1) BR0212915A (pt)
CA (1) CA2465776A1 (pt)
CO (1) CO5580790A2 (pt)
CY (1) CY1106765T1 (pt)
DE (1) DE60220084T2 (pt)
DK (1) DK1446131T3 (pt)
EA (1) EA007325B1 (pt)
EC (1) ECSP045041A (pt)
ES (1) ES2287343T3 (pt)
GE (1) GEP20074097B (pt)
HK (1) HK1070561A1 (pt)
HR (1) HRP20040303B1 (pt)
HU (1) HU228959B1 (pt)
IL (2) IL161114A0 (pt)
IS (1) IS2484B (pt)
MA (1) MA27071A1 (pt)
ME (2) ME00229B (pt)
MX (1) MXPA04003045A (pt)
NO (1) NO20041320L (pt)
NZ (1) NZ552129A (pt)
PE (1) PE20030740A1 (pt)
PL (1) PL206008B1 (pt)
PT (1) PT1446131E (pt)
RS (1) RS50906B (pt)
SI (1) SI1446131T1 (pt)
UA (1) UA80399C2 (pt)
WO (1) WO2003041722A1 (pt)
ZA (1) ZA200402464B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075910A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fondaparinux
BR112017020091A2 (pt) * 2015-03-20 2018-11-06 Aarhus Universitet inibidores de pcsk9 para tratamento de distúrbios do metabolismo de lipoproteínas
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN107595769A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种磺达肝癸钠注射液组合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
CA2199642C (en) * 1997-03-10 2001-05-08 Roger Cariou Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US20040087543A1 (en) * 2002-04-25 2004-05-06 Zachary Shriver Methods and products for mucosal delivery

Also Published As

Publication number Publication date
ZA200402464B (en) 2005-06-29
AU2002351915B2 (en) 2007-11-29
PT1446131E (pt) 2007-08-07
DK1446131T3 (da) 2007-09-10
ME00229B (me) 2011-10-10
HU228959B1 (en) 2013-07-29
HRP20040303A2 (en) 2004-10-31
US20040248848A1 (en) 2004-12-09
MXPA04003045A (es) 2005-06-20
HK1070561A1 (en) 2005-06-24
DE60220084D1 (de) 2007-06-21
MA27071A1 (fr) 2004-12-20
IL161114A0 (en) 2004-08-31
MEP1108A (en) 2011-02-10
RS26704A (en) 2007-02-05
KR20050044318A (ko) 2005-05-12
CA2465776A1 (en) 2003-05-22
CO5580790A2 (es) 2005-11-30
AP1820A (en) 2008-01-11
EA007325B1 (ru) 2006-08-25
GEP20074097B (en) 2007-05-10
JP2005509007A (ja) 2005-04-07
EP1446131B1 (en) 2007-05-09
DE60220084T2 (de) 2008-01-10
HUP0401462A2 (en) 2006-02-28
EA200400382A1 (ru) 2004-10-28
IS7199A (is) 2004-03-29
RS50906B (sr) 2010-08-31
CY1106765T1 (el) 2012-05-23
AP2004003014A0 (en) 2004-06-30
NZ552129A (en) 2008-04-30
CN1602197A (zh) 2005-03-30
HUP0401462A3 (en) 2006-04-28
AR037291A1 (es) 2004-11-03
ES2287343T3 (es) 2007-12-16
IS2484B (is) 2008-12-15
UA80399C2 (en) 2007-09-25
ATE361753T1 (de) 2007-06-15
JP4523276B2 (ja) 2010-08-11
EP1446131A1 (en) 2004-08-18
PL369027A1 (en) 2005-04-18
IL161114A (en) 2010-11-30
ECSP045041A (es) 2004-04-28
SI1446131T1 (sl) 2007-10-31
PE20030740A1 (es) 2003-08-28
HRP20040303B1 (en) 2012-02-29
NO20041320L (no) 2004-06-14
WO2003041722A1 (en) 2003-05-22
PL206008B1 (pl) 2010-06-30

Similar Documents

Publication Publication Date Title
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BR0015188A (pt) Composições farmacêuticas
DE60323756D1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
EP1024145A3 (en) Novel azalides and methods of making same
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
DE60131703D1 (de) Orale feste pharmazeutische Zusammensetzungen zur pH-abhängig mehrphasigen Freisetzung
AU2002243387A1 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
BR0111034A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids
BR0113663A (pt) Composições de pelìcula de pectina
AR033688A1 (es) Composicion parenteral reconstituible
AP2002002674A0 (en) Clear Aqueous Anaesthetic composition.
DK0538011T3 (da) Saltsammensætninger omfattende lipofilt oligosaccharidantibiotikum.
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
ATE422356T1 (de) Pharmazeutische zubereitungen
BRPI0409413A (pt) composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
CY1106765T1 (el) Χρηση ειδικης δοσης του νατριουχου φονταπαρινιδιου για τη θεραπεια των acs
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0011845A (pt) Complexo farmacêutico
JP2005509007A5 (pt)
BRPI0413032A (pt) diamidas de aminoacidos em uma posição não-(alfa), úteis como adjuvantes na administração de agentes biológicos ativos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B25A Requested transfer of rights approved

Owner name: GLAXO GROUP LIMITED (GB)

Free format text: TRANSFERIDO DE: SANOFI-AVENTIS

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.